wehewehe

ʻO Lenalidomide (CC-5013) kahi huaʻōlelo o Thalidomide a me kahi immunomodulator hoʻoikaika waha.ʻO Lenalidomide (CC-5013) kahi ligand o ka ubiquitin E3 ligase cereblon (CRBN), a ke kumu ia i ka ubiquitination koho a me ka hoʻohaʻahaʻa ʻana o nā mea transcription lymphoid ʻelua, IKZF1 a me IKZF3, e ka CRBN-CRL4 ubiquitin ligase.ʻO Lenalidomide (CC-5013) kaohi pono i ka ulu ʻana o nā lymphomas B-cell makua, me ka myeloma lehulehu, a hoʻoulu i ka hoʻokuʻu ʻana o IL-2 mai nā pūnaewele T.

Ka hope

ʻO Lenalidomide (ʻike pū ʻia ʻo CC-5013), he ʻano oral derivative o thalidomide, he antineoplastic agent e hōʻike ana i ka hana antitumor ma o nā ʻano hana like ʻole, me ka hoʻoulu ʻana o ka ʻōnaehana pale, ka inhibition angiogenesis, a me nā hopena antineoplastic pololei.Ua aʻo nui ʻia no ka mālama ʻana i ka myeloma lehulehu a me ka myelodysplastic syndrome a me nā maʻi lymphoproliferative e pili ana i ka maʻi lymphocytic leukemia (CLL) a me ka lymphoma non-Hodgkin.Wahi a nā noiʻi hou loa, hoʻolalelale ʻo Lnalidomide a hoʻihoʻi i ka hana ʻōnaehana immune i nā maʻi CLL ma o ka hoʻoulu ʻana i ka overexpression o nā molekala costimulatory i loko o nā lymphocytes leukemic e hoʻihoʻi i ka hoʻomaʻamaʻa humoral a me ka hana immunoglobulins a me ka hoʻomaikaʻi ʻana i ka hiki o nā cell T a me nā cell leukemic e hana i nā synapses me T lymphocytes.

Kuhikuhi

Ana Pilar Gonzalez-Rodriguez, Angel R. Payer, Andrea Acebes-Huerta, Leticia Hergo-Zapico, Monica Villa-Alvarez, Esther Gonzalez-Garcia, and Segundo Gonzalez.Lenalidomide a me ka leukemia lymphocytic mau loa.BioMed Research International 2013.

In Vitro

He ikaika ka Lenalidomide i ka hoʻoulu ʻana i ka hoʻonui ʻana o ka cell T a me IFN-γ a me ka hana IL-2.Ua hōʻike ʻia ʻo Lenalidomide e kāohi i ka hana ʻana o nā cytokine pro inflammatory TNF-α, IL-1, IL-6, IL-12 a hoʻokiʻekiʻe i ka hana o anti-inflammatory cytokine IL-10 mai nā PBMC kanaka.Hoʻohaʻahaʻa ʻo Lenalidomide i ka hana ʻana o ka IL-6 pololei a me ka hoʻopaʻa ʻana i nā pūnaewele myeloma (MM) a me ka launa pū ʻana o ka iwi marrow stromal cell (BMSC), e hoʻonui ana i ka apoptosis o nā cell myeloma [2].ʻIke ʻia ka launa pū ʻana me ka CRBN-DDB1 complex me Thalidomide, Lenalidomide a me Pomalidomide, me nā waiwai IC50 o ~30μM, ~3μM a me ~3μM, kēlā me kēia, ʻO kēia mau pūnaewele hōʻike CRBN i hōʻemi ʻia (U266-CRBN60 a me U266-CRBN75) ʻoi aku ka liʻiliʻi o ka pane ʻana ma mua o nā cell makua i nā hopena antiproliferative Lenalidomide ma waena o kahi pae pane-pane o 0.01 a 10.μM[3].ʻO Lenalidomide, kahi analog thalidomide, hana ma ke ʻano he molecular glue ma waena o ke kanaka E3 ubiquitin ligase cereblon a me CKIα hōʻike ʻia e hoʻoulu i ka ubiquitination a me ka hoʻohaʻahaʻa ʻana o kēia kinase, no laila ke pepehi ʻia nei nā cell leukemic e ka p53 activation.

ʻO ka ʻawaʻawa o Lenalidomide a hiki i ka 15, 22.5, a me 45 mg/kg ma o nā ala IV, IP, a me PO o ka hoʻokele.Hoʻopaʻa ʻia e ka solubility i loko o kā mākou PBS dosing kaʻa, ʻae maikaʻi ʻia kēia mau kikoʻī Lenalidomide kiʻekiʻe loa me ka ʻokoʻa o hoʻokahi make ʻiole (o ʻehā mau dosed) ma ka 15 mg/kg IV.ʻO ka mea nui, ʻaʻohe mea ʻona ʻē aʻe i ʻike ʻia ma ke aʻo ʻana ma nā kaila IV o 15 mg/kg (n=3) a i ʻole 10 mg/kg (n=45) a i ʻole ma kekahi pae pae ma o nā ala IV, IP, a me PO.

Waihona

ʻO ke kinona

ʻIkepili olaola pili

ʻIkepili olaola pili